{"id":"NCT04178967","sponsor":"Eli Lilly and Company","briefTitle":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis","officialTitle":"A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-29","primaryCompletion":"2021-07-12","completion":"2022-04-28","firstPosted":"2019-11-26","resultsPosted":"2022-09-16","lastUpdate":"2023-05-24"},"enrollment":445,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"BIOLOGICAL","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lebrikizumab Q2W","type":"EXPERIMENTAL"},{"label":"Lebrikizumab Q4W","type":"EXPERIMENTAL"},{"label":"Escape Arm (Lebrikizumab Q2W)","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.","primaryOutcome":{"measure":"Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction â‰¥2 Points From Baseline to Week 16","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Placebo","deltaMin":10.8,"sd":null},{"arm":"Lebrikizumab Q2W","deltaMin":33.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.000004"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":89,"countries":["United States","Bulgaria","Canada","Germany","Mexico","Singapore","Taiwan","Ukraine"]},"refs":{"pmids":["40663228","39249591","39123054","39002092","38922484","38700646","38679419","36994947","36920778"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/AmPN68cQaViDZ8pT3j6hD"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":149},"commonTop":["Dermatitis atopic","Nasopharyngitis","Conjunctivitis","Headache","Conjunctivitis allergic"]}}